South Korea’s Hanmi Pharmaceutical Launches Obesity Drug EPPE on Oct. 29 at approximately $98 per 4-Week Supply — BigGo Finance
South Korea’s Hanmi Pharmaceutical will begin prescribing its domestically developed obesity treatment EPPE (active ingredient efpeglenatide) at some…
#EuropeSays #Korea #KR #Celltrion #EPPE #HanmiPharmaceutical #Kaigene #KG013 #Korean #Mounjaro #SamsungBiologics #SouthKorea'sMinistryofFoodandDrugSafety #Wegovy
https://www.europesays.com/korea/199637/